236 related articles for article (PubMed ID: 23406016)
21. Identification of Prostaglandin F2 Receptor Negative Regulator (PTGFRN) as an internalizable target in cancer cells for antibody-drug conjugate development.
Marquez J; Dong J; Dong C; Tian C; Serrero G
PLoS One; 2021; 16(1):e0246197. PubMed ID: 33503070
[TBL] [Abstract][Full Text] [Related]
22. CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.
Turcotte M; Allard D; Mittal D; Bareche Y; Buisseret L; José V; Pommey S; Delisle V; Loi S; Joensuu H; Kellokumpu-Lehtinen PL; Sotiriou C; Smyth MJ; Stagg J
Cancer Res; 2017 Oct; 77(20):5652-5663. PubMed ID: 28855210
[TBL] [Abstract][Full Text] [Related]
23. Chemotherapy induces enrichment of CD47
Samanta D; Park Y; Ni X; Li H; Zahnow CA; Gabrielson E; Pan F; Semenza GL
Proc Natl Acad Sci U S A; 2018 Feb; 115(6):E1239-E1248. PubMed ID: 29367423
[TBL] [Abstract][Full Text] [Related]
24. High-content analysis of antibody phage-display library selection outputs identifies tumor selective macropinocytosis-dependent rapidly internalizing antibodies.
Ha KD; Bidlingmaier SM; Zhang Y; Su Y; Liu B
Mol Cell Proteomics; 2014 Dec; 13(12):3320-31. PubMed ID: 25149096
[TBL] [Abstract][Full Text] [Related]
25. CD73 blockade enhances the local and abscopal effects of radiotherapy in a murine rectal cancer model.
Tsukui H; Horie H; Koinuma K; Ohzawa H; Sakuma Y; Hosoya Y; Yamaguchi H; Yoshimura K; Lefor AK; Sata N; Kitayama J
BMC Cancer; 2020 May; 20(1):411. PubMed ID: 32397971
[TBL] [Abstract][Full Text] [Related]
26. Discovery of internalizing antibodies to basal breast cancer cells.
Zhou Y; Zou H; Yau C; Zhao L; Hall SC; Drummond DC; Farr-Jones S; Park JW; Benz CC; Marks JD
Protein Eng Des Sel; 2018 Jan; 31(1):17-28. PubMed ID: 29301020
[TBL] [Abstract][Full Text] [Related]
27. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
Allard B; Turcotte M; Stagg J
Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
[TBL] [Abstract][Full Text] [Related]
28. A novel inhibitory anti-invasive MAb isolated using phenotypic screening highlights AnxA6 as a functionally relevant target protein in pancreatic cancer.
O'Sullivan D; Dowling P; Joyce H; McAuley E; McCann A; Henry M; McGovern B; Barham P; Kelleher FC; Murphy J; Kennedy S; Swan N; Moriarty M; Clynes M; Larkin A
Br J Cancer; 2017 Oct; 117(9):1326-1335. PubMed ID: 28881357
[TBL] [Abstract][Full Text] [Related]
29. Agonists and antagonists of GnRH-I and -II reduce metastasis formation by triple-negative human breast cancer cells in vivo.
Schubert A; Hawighorst T; Emons G; Gründker C
Breast Cancer Res Treat; 2011 Dec; 130(3):783-90. PubMed ID: 21279682
[TBL] [Abstract][Full Text] [Related]
30. A highly potent CD73 biparatopic antibody blocks organization of the enzyme active site through dual mechanisms.
Stefano JE; Lord DM; Zhou Y; Jaworski J; Hopke J; Travaline T; Zhang N; Wong K; Lennon A; He T; Bric-Furlong E; Cherrie C; Magnay T; Remy E; Brondyk W; Qiu H; Radošević K
J Biol Chem; 2020 Dec; 295(52):18379-18389. PubMed ID: 33122192
[TBL] [Abstract][Full Text] [Related]
31. The indole-3-carbinol cyclic tetrameric derivative CTet inhibits cell proliferation via overexpression of p21/CDKN1A in both estrogen receptor-positive and triple-negative breast cancer cell lines.
De Santi M; Galluzzi L; Lucarini S; Paoletti MF; Fraternale A; Duranti A; De Marco C; Fanelli M; Zaffaroni N; Brandi G; Magnani M
Breast Cancer Res; 2011 Mar; 13(2):R33. PubMed ID: 21435243
[TBL] [Abstract][Full Text] [Related]
32. CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer.
Petruk N; Tuominen S; Åkerfelt M; Mattsson J; Sandholm J; Nees M; Yegutkin GG; Jukkola A; Tuomela J; Selander KS
Sci Rep; 2021 Mar; 11(1):6035. PubMed ID: 33727591
[TBL] [Abstract][Full Text] [Related]
33. Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers.
Nagano K; Maeda Y; Kanasaki S; Watanabe T; Yamashita T; Inoue M; Higashisaka K; Yoshioka Y; Abe Y; Mukai Y; Kamada H; Tsutsumi Y; Tsunoda S
J Control Release; 2014 Sep; 189():72-9. PubMed ID: 24946238
[TBL] [Abstract][Full Text] [Related]
34. Screening and characterization of novel specific peptides targeting MDA-MB-231 claudin-low breast carcinoma by computer-aided phage display methodologies.
Nobrega FL; Ferreira D; Martins IM; Suarez-Diez M; Azeredo J; Kluskens LD; Rodrigues LR
BMC Cancer; 2016 Nov; 16(1):881. PubMed ID: 27842517
[TBL] [Abstract][Full Text] [Related]
35. Patient-derived heavy chain antibody targets cell surface HSP90 on breast tumors.
Devarakonda CV; Kita D; Phoenix KN; Claffey KP
BMC Cancer; 2015 Sep; 15():614. PubMed ID: 26334999
[TBL] [Abstract][Full Text] [Related]
36. Luteolin exerts anti-tumor activity through the suppression of epidermal growth factor receptor-mediated pathway in MDA-MB-231 ER-negative breast cancer cells.
Lee EJ; Oh SY; Sung MK
Food Chem Toxicol; 2012 Nov; 50(11):4136-43. PubMed ID: 22926442
[TBL] [Abstract][Full Text] [Related]
37. Mass spectrometry (LC-MS/MS) identified proteomic biosignatures of breast cancer in proximal fluid.
Whelan SA; He J; Lu M; Souda P; Saxton RE; Faull KF; Whitelegge JP; Chang HR
J Proteome Res; 2012 Oct; 11(10):5034-45. PubMed ID: 22934887
[TBL] [Abstract][Full Text] [Related]
38. ErbB-inhibitory protein: a modified ectodomain of epidermal growth factor receptor synergizes with dasatinib to inhibit growth of breast cancer cells.
Nautiyal J; Yu Y; Aboukameel A; Kanwar SS; Das JK; Du J; Patel BB; Sarkar FH; Rishi AK; Mohammad RM; Majumdar AP
Mol Cancer Ther; 2010 Jun; 9(6):1503-14. PubMed ID: 20515951
[TBL] [Abstract][Full Text] [Related]
39. Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy.
Girgert R; Emons G; Gründker C
Breast Cancer Res Treat; 2012 Jul; 134(1):199-205. PubMed ID: 22290080
[TBL] [Abstract][Full Text] [Related]
40. Combinatorial effects of lapatinib and rapamycin in triple-negative breast cancer cells.
Liu T; Yacoub R; Taliaferro-Smith LD; Sun SY; Graham TR; Dolan R; Lobo C; Tighiouart M; Yang L; Adams A; O'Regan RM
Mol Cancer Ther; 2011 Aug; 10(8):1460-9. PubMed ID: 21690228
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
